Avantogen’s Hawaii Biotech Inc. receives clinical trial support from Walter Reed Army Institute of Research
Avantogen believes that a partnership with a reputable organisation such as WRAIR gives further validation of the Hawaii Biotech Inc vaccine technology platform and the actual dengue vaccine candidate that has been developed. Furthermore, Avantogen (and Hawaii Biotech Inc) have also gained a potential partner to accelerate the program. Next steps could be the dosage of first subjects with the proprietary, recombinant-DNA-based vaccine candidate being developed by Hawaii Biotech Inc.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.